Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Coeptis Therapeutics Holdings, Inc. - Common Stock (NQ: COEP )

10.34 +0.83 (+8.73%)
Streaming Delayed Price Updated: 12:00 PM EST, Jan 22, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Coeptis Therapeutics Holdings, Inc. - Common Stock

Coeptis Therapeutics (Nasdaq: COEP) Emerges as a Biopharma Innovator Leveraging AI-Driven Marketing
Via AB Newswire
Topics Artificial Intelligence
Exposures Artificial Intelligence
Biotech Innovation: Coeptis Therapeutics (COEP) And 3 Companies Changing The Game
Via Get News
Biotech Bright Spots: Coeptis Therapeutics (COEP) And 3 Hidden Treasures
Via Get News
These are the 4 hottest stocks insiders bought in January
Insiders are buying these stocks, but not all are good buys for investors or bullish traders; avoid stocks with high short interest, no revenue, and no earnings 
Via MarketBeat
Potential acquisition of VyGen-Bio would Strengthen Coeptis Therapeutics (NASDAQ: COEP) oncology pipeline by obtaining exclusive, worldwide ownership rights to GEAR™ Platform
Via Get News
Acquisition Rights Obtained for Combinatorial Immuno-Oncology Treatments Using Multi-Antigen CAR T Technology, Cell Therapy for Multiple Cancers: Coeptis Therapeutics (NASDAQ: COEP)
Via Get News
BioMedNewsBreaks – Coeptis Therapeutics Holdings Inc. (NASDAQ: COEP) Tech Spotlighted in Article in Peer-Reviewed Translational Medicine Journal
Via Investor Brand Network
Translational Medicine Journal Features Multi-Antigen CAR T Technology, Cell Therapy, and In Vitro Diagnostics with Multiple Cancer Types: Coeptis Therapeutics Holdings, Inc (NASDAQ: COEP)
Via Get News
Coeptis Therapeutics Holdings, Inc (NASDAQ: COEP) to Collaborate with the University of Pittsburgh to expand pre-clinical Development of SNAP-CAR T Cells Targeting HER2-Positive Cancers
Via Get News
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.